Janus Henderson Group PLC Reduces Stock Position in Baxter International Inc (NYSE:BAX)

Janus Henderson Group PLC cut its holdings in Baxter International Inc (NYSE:BAX) by 22.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 2,640,819 shares of the medical instruments supplier’s stock after selling 764,464 shares during the period. Janus Henderson Group PLC’s holdings in Baxter International were worth $220,820,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Stifel Financial Corp boosted its holdings in shares of Baxter International by 66.9% in the fourth quarter. Stifel Financial Corp now owns 1,082,066 shares of the medical instruments supplier’s stock worth $91,214,000 after acquiring an additional 433,693 shares during the period. Evoke Wealth LLC bought a new position in shares of Baxter International in the third quarter worth $436,000. Pearl River Capital LLC boosted its holdings in shares of Baxter International by 316.2% in the fourth quarter. Pearl River Capital LLC now owns 4,162 shares of the medical instruments supplier’s stock worth $348,000 after acquiring an additional 3,162 shares during the period. Metropolitan Life Insurance Co NY boosted its holdings in shares of Baxter International by 17.2% in the third quarter. Metropolitan Life Insurance Co NY now owns 87,294 shares of the medical instruments supplier’s stock worth $7,636,000 after acquiring an additional 12,809 shares during the period. Finally, Cerebellum GP LLC boosted its holdings in shares of Baxter International by 31.1% in the fourth quarter. Cerebellum GP LLC now owns 6,654 shares of the medical instruments supplier’s stock worth $556,000 after acquiring an additional 1,580 shares during the period. 83.10% of the stock is owned by institutional investors.

Shares of NYSE:BAX opened at $73.57 on Thursday. The company’s fifty day moving average price is $85.94 and its 200-day moving average price is $85.14. The firm has a market capitalization of $37.49 billion, a price-to-earnings ratio of 22.23, a PEG ratio of 1.77 and a beta of 1.00. Baxter International Inc has a one year low of $69.10 and a one year high of $95.00. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.32 and a quick ratio of 1.81.

Baxter International (NYSE:BAX) last posted its quarterly earnings data on Tuesday, March 17th. The medical instruments supplier reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.09. Baxter International had a net margin of 9.12% and a return on equity of 22.41%. The company had revenue of $2.85 billion during the quarter, compared to the consensus estimate of $2.87 billion. During the same period in the previous year, the firm posted $0.80 EPS. The firm’s revenue was up .4% compared to the same quarter last year. As a group, equities research analysts expect that Baxter International Inc will post 3.56 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Friday, February 28th will be given a dividend of $0.22 per share. The ex-dividend date is Thursday, February 27th. This represents a $0.88 dividend on an annualized basis and a yield of 1.20%. Baxter International’s payout ratio is 26.59%.

A number of research firms have recently commented on BAX. SVB Leerink reaffirmed an “outperform” rating on shares of Baxter International in a report on Tuesday, March 17th. KeyCorp raised Baxter International from a “sector weight” rating to an “overweight” rating and set a $92.00 price target for the company in a report on Wednesday, March 18th. Stifel Nicolaus raised Baxter International from a “hold” rating to a “buy” rating and raised their price target for the stock from $87.00 to $95.00 in a report on Thursday, March 19th. Morgan Stanley raised Baxter International from an “equal weight” rating to an “overweight” rating in a report on Thursday, January 2nd. Finally, Cfra raised their price target on Baxter International from $87.00 to $93.00 and gave the stock a “hold” rating in a report on Thursday, February 6th. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $92.16.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Further Reading: How does the Beige Book influence monetary policy?

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.